Literature DB >> 12138349

The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 Cell counts to chronic mortality.

George R Seage1, Elena Losina, Sue J Goldie, A David Paltiel, April D Kimmel, Kenneth A Freedberg.   

Abstract

BACKGROUND: Both HIV-1 RNA and absolute CD4 cell counts have been identified as important predictors of HIV-1 disease progression and mortality. The independent impact of opportunistic infections on the risk of chronic mortality, defined as death beyond 30 days of an opportunistic infection, has not been studied when controlling for HIV-1 RNA. Our objective was to determine the relationship between a history of any of five preventable opportunistic infections (Pneumocystis carinii pneumonia, Mycobacterium avium complex, toxoplasmosis, cytomegalovirus, and candida esophagitis) and chronic mortality.
METHODS: Using the Multicenter AIDS Cohort Study (MACS) public use data set of 2193 HIV-infected men in four U.S. cities, we employed a Cox regression model to estimate the impact of a history of preventable opportunistic infection on chronic mortality while controlling for maximum HIV-1 RNA, CD4 cell count, use of antiretroviral drugs, and age.
FINDINGS: The chronic mortality rate among individuals with a history of preventable opportunistic infection was 66.7 per 100 person-years compared with 2.3 per 100 person-years for those without a history of preventable opportunistic infection (RR = 28.4, 95% CI: 24.7-32.8). In the adjusted analysis, the relative hazard of death for those with a history of preventable opportunistic infections was 7.0 (5.8-8.3), whereas antiretroviral therapy was associated with a decreased risk of death (0.37 [0.30-0.44]). We found no association between maximum HIV-1 RNA and chronic mortality. There was statistically significant effect modification between preventable opportunistic infections and CD4 cell count (p <.0001).
INTERPRETATION: Preventable opportunistic infections cause not only short-term mortality in HIV-1 disease but appear to have a major impact on chronic mortality.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12138349     DOI: 10.1097/00042560-200208010-00008

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  9 in total

1.  Spectrum of AIDS Defining Opportunistic Infections in a Series of 77 Hospitalised HIV-infected Omani Patients.

Authors:  Abdullah A Balkhair; Zakariya K Al-Muharrmi; Shyam Ganguly; Ali A Al-Jabri
Journal:  Sultan Qaboos Univ Med J       Date:  2012-11-20

2.  Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Côte d'Ivoire: impact of alternative methods of CD4 count modelling.

Authors:  Sylvie Deuffic-Burban; Elena Losina; Bingxia Wang; Delphine Gabillard; Eugène Messou; Nomita Divi; Kenneth A Freedberg; Xavier Anglaret; Yazdan Yazdanpanah
Journal:  Eur J Epidemiol       Date:  2007-09-08       Impact factor: 8.082

3.  N9-substituted 2,4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of pneumocystis carinii and toxoplasma gondii dihydrofolate reductase.

Authors:  Aleem Gangjee; Ona O Adair; Michelle Pagley; Sherry F Queener
Journal:  J Med Chem       Date:  2008-09-05       Impact factor: 7.446

4.  Imidazoquines as antimalarial and antipneumocystis agents.

Authors:  Nuno Vale; Miguel Prudêncio; Catarina A Marques; Margaret S Collins; Jiri Gut; Fátima Nogueira; Joana Matos; Philip J Rosenthal; Melanie T Cushion; Virgílio E do Rosário; Maria M Mota; Rui Moreira; Paula Gomes
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

5.  Assessing the performance of a computer-based policy model of HIV and AIDS.

Authors:  Chara E Rydzak; Kara L Cotich; Paul E Sax; Heather E Hsu; Bingxia Wang; Elena Losina; Kenneth A Freedberg; Milton C Weinstein; Sue J Goldie
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

6.  Medicaid Managed Care and Racial Disparities in AIDS Treatment.

Authors:  James M Guwani; Robert Weech-Maldonado
Journal:  Health Care Financ Rev       Date:  2004

7.  Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity.

Authors:  F Ratzinger; H Haslacher; W Poeppl; G Hoermann; J J Kovarik; S Jutz; P Steinberger; H Burgmann; W F Pickl; K G Schmetterer
Journal:  Sci Rep       Date:  2014-12-11       Impact factor: 4.379

8.  Lower Viral Loads and Slower CD4+ T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02.

Authors:  Ellen M Leitman; Jacob Hurst; Masahiko Mori; James Kublin; Thumbi Ndung'u; Bruce D Walker; Jonathan Carlson; Glenda E Gray; Philippa C Matthews; Nicole Frahm; Philip J R Goulder
Journal:  J Infect Dis       Date:  2016-03-06       Impact factor: 5.226

9.  Opportunistic diseases among HIV-infected patients: a multicenter-nationwide Korean HIV/AIDS cohort study, 2006 to 2013.

Authors:  Youn Jeong Kim; Jun Hee Woo; Min Ja Kim; Dae Won Park; Joon-Young Song; Shin Woo Kim; Jun Yong Choi; June Myung Kim; Sang Hoon Han; Jin-Soo Lee; Bo Youl Choi; Joo Shil Lee; Sung-Soon Kim; Mee-Kyung Kee; Moon Won Kang; Sang Il Kim
Journal:  Korean J Intern Med       Date:  2016-04-27       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.